Gwenn Hansen - 03 Feb 2026 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Chief Scientific Officer
Signature
/s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen
Issuer symbol
NRIX
Transactions as of
03 Feb 2026
Net transactions value
+$26,320
Form type
4
Filing time
03 Feb 2026, 21:12:37 UTC
Previous filing
30 Jan 2026
Next filing
10 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hansen Gwenn Chief Scientific Officer C/O NURIX THERAPEUTICS, INC., 1600 SIERRA POINT PKWY, BRISBANE /s/ Daniel Burbach, as Attorney-in-Fact for Gwenn Hansen 03 Feb 2026 0001817160

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRIX Common Stock Options Exercise $26,320 +31,333 +37% $0.8400 115,005 03 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Employee Stock Option (right to buy) Options Exercise $0 -31,333 -100% $0.000000 0 03 Feb 2026 Common Stock 31,333 $0.8400 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option is fully vested.